$11.565
-0.279 (-2.41%)Zum Schluss
ZVRA-News
ZVRA-Events
Zevra Q2 Revenue at $30.2M, Below Consensus
Reports Q2 revenue $30.2M, consensus $33.88M. "Zevra delivered strong MIPLYFFA performance and further established the therapy as an important treatment option for people living with Niemann-Pick disease type C," said Neil F. McFarlane, Zevra's President and Chief Executive Officer. "These results reflect the strength of our U.S. commercial execution. Additionally, we are pursuing access to arimoclomol for people living with NPC in Europe, and we have submitted a request for the re-examination of our Marketing Authorisation Application. Our global Expanded Access Program remains active for eligible patients, reflecting our steadfast commitment to patients and families."
Spruce Biosciences Appoints Quartel as Chief Medical Officer
Spruce Biosciences (SPRB) announced the appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer, effective today. Quartel joins Spruce from Zevra Therapeutics (ZVRA), where he served as Chief Medical Officer
Intel Beats Q2 Expectations as Stocks Show Mixed Performance
The major averages had a mixed Friday as stocks attempted to recover from Thursday's tech-led selloff. Intel saw weakness despite a Q2 beat and technology remains the market's primary focus after Alphabet and Tesla sparked the biggest one-day decline in the S&P 500 and Nasdaq in about a month. Investors have grown increasingly concerned that soaring capital expenditures and cash burn tied to artificial intelligence may take longer to generate meaningful returns.In macro news, Pakistan is exploring a path towards a resumption of stalled talks between the U.S. and Iran, three Pakistani sources told Reuters. Although crude oil prices pulled back from their overnight highs, the commodity advanced for the week.Additionally, U.S. President Donald Trump said in a social media post that the European Union "will pay a very big price" for fines against U.S. tech companies. "The penalties will be entirely reversed and, we anticipate, a substantial TARIFF to be placed on them at the earliest possible moment," Trump.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Intelreportedand provided upbeat Q3 earnings and revenue guidanceVerizonprovided afor Q2American Expressreportedand reaffirmed its FY26 earnings outlookDefense technology company Anduril is in talks to raise funding at a roughly $100B valuation,Payment processor Stripe, which is still mulling its next move with respect to a deal for PayPal, is in discussions to acquire AI model marketplace OpenRouter,2. WALL STREET CALLS:HSBC "prudent" on futuristic calls for SpaceX,Cheesecake Factoryto Neutral at MizuhoPayPalto Hold from Sell at TruistAlbertsonsat BMO Capital and Telsey AdvisoryEdwards Lifesciencesto Outperform at Leerink3. AROUND THE WEB:Bidding for MarineMaxhas moved into a third round and Blackstone, Donerail and private equity firm Centerbridge are among the final bidders to acquire the recreational yacht retailer, Reuters reportsRivianis suing the U.S. government in an effort to claw back a "full refund" on tariffs it paid under President Trump's "Liberation Day" tariffs, TechCrunch reportsAlphabet'sWaymo is weighing options to split from its Uberpartnership, FT reportsBPis in advanced talks to sell its solar power arm Lightsource to Qualitas Energy, a private equity firm focused on green energy, and Wren House, the infrastructure arm of Kuwait Investment Authority, FT saysThe pause on Paramount Skydance'sproposed $110B takeover of Warner Bros. Discoveryhas been extended to August 17 from August 3 by a U.S. judge, Bloomberg reports4. MOVERS:RingCentralgained after, increasing its guidance for FY26, and raising its quarterly dividendTenet Healthcarewas higher afterand authorizing a $2B increase to its share repurchase programDigital Realtyand Booz Allenincreased afterZevra Therapeuticswas lower after announcing the CHMP of the EMAregarding the MAA for arimoclomolMaxLinearand Summit Therapeuticsfell after5. EARNINGS/GUIDANCE:HCA Healthcareand cut its guidance for FY26Charter, with EPS and revenue beating consensusNextEra Energy, with CEO John Ketchum commenting, "NextEra Energy delivered a strong Q2, with adjusted earnings per share increasing by 9.5% year-over-yearSensientand raised its guidance for FY26Gentex, with CEO Steve Downing commenting, ""Our second quarter results demonstrate the importance of our strategy to grow through technology, product mix, and diversification"INDEXES:The Dow rose 235.60, or 0.46%, to 51,947.25, the Nasdaq lost 161.87, or 0.64%, to 24,975.82, and the S&P 500 advanced 3.68, or 0.05%, to 7,411.98.
Major Averages Rebound as Intel Reports Strong Q2 Earnings
The major averages were higher near noon as stocks look to recover from Thursday's tech-led selloff. Intel is seeing weakness despite a Q2 beat and technology remains the market's primary focus after Alphabet and Tesla sparked the biggest one-day decline in the S&P 500 and Nasdaq in about a month. Investors have grown increasingly concerned that soaring capital expenditures and cash burn tied to artificial intelligence may take longer to generate meaningful returns.Meanwhile, Pakistan is exploring a path towards a resumption of stalled talks between the U.S. and Iran, three Pakistani sources told Reuters. Although crude has pulled back from its overnight highs, it remains higher for the week.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Intelreportedand provided sharply upbeat Q3 earnings and revenue guidanceVerizonprovided areport for Q2American Expressreportedand reaffirmed its FY26 earnings outlookDefense technology company Anduril is in talks to raise funding at a roughly $100B valuation,Payment processor Stripe, which is still mulling its next move with respect to a deal for PayPalis in discussions to acquire AI model marketplace OpenRouter,2. WALL STREET CALLS:HSBC "prudent" on futuristic calls for SpaceX,with Hold ratingCheesecake Factoryto Neutral at MizuhoPayPalto Hold from Sell at TruistAlbertsonsat BMO Capital and Telsey AdvisoryEdwards Lifesciencesto Outperform at Leerink3. AROUND THE WEB:Amazonis shuttering its AGI Lab as part of layoffs in its AGI unit earlier this week, The Information saysSoftBankis considering an acquisition of Gravis Robotics in a deal that would value the startup at more than $500M, Bloomberg reportsNestlehas been lobbying U.S. authorities to allow simpler descriptions on packaging rather than scientific names, Reuters reportsBPis in advanced talks to sell its solar power arm Lightsource to Qualitas Energy, a private equity firm focused on green energy, and Wren House, the infrastructure arm of Kuwait Investment Authority, FT saysThe pause on Paramount Skydance'sproposed $110B takeover of Warner Bros. Discoveryhas been extended to August 17 from August 3 by U.S. District Judge Araceli Martinez-Olguin, Bloomberg reports4. MOVERS:RingCentralgains after, increasing its guidance for FY26, and raising its quarterly dividendTenet Healthcarehigher afterand authorizing a $2B increase to its share repurchase programDigital Realtyand Booz Allenincrease afterZevra Therapeuticslower after announcing the CHMP of the EMAregarding the MAA for arimoclomolMaxLinearand Summit Therapeuticsfall after5. EARNINGS/GUIDANCE:HCA Healthcareand cut its guidance for FY26Charter, with EPS and revenue beating consensusNextEra Energy, with CEO John Ketchum commenting, "NextEra Energy delivered a strong Q2, with adjusted earnings per share increasing by 9.5% year-over-yearSensientand raised its guidance for FY26Gentex, with CEO Steve Downing commenting, ""Our second quarter results demonstrate the importance of our strategy to grow through technology, product mix, and diversification"INDEXES:Near midday, the Dow was up 354.51, or 0.69%, to 52,066.16, the Nasdaq was up 58.28, or 0.23%, to 25,195.97, and the S&P 500 was up 46.80, or 0.63%, to 7,455.10.
Intel Delivers Strong Earnings, Boosts Stock Futures
Stock futures are modestly higher Friday as investors attempt to recover from Thursday's sharp technology-led selloff with Intel providing support after delivering stronger-than-expected earnings and an upbeat outlook.Technology remains the market's primary focus after Alphabet and Tesla sparked the biggest one-day decline in the S&P 500 and Nasdaq in about a month. Investors have grown increasingly concerned that soaring capital expenditures and cash burn tied to artificial intelligence may take longer to generate meaningful returns. Intel helped ease some of those concerns after beating quarterly expectations, forecasting stronger revenue and profit for the current quarter, and outlining plans to continue investing in AI and manufacturing capacity.Oil prices surged above $100 per barrel following renewed attacks on shipping linked to Iran-backed Houthi militants in the Red Sea, heightening fears of supply disruptions and adding to inflation concerns. Although crude has pulled back slightly from its overnight highs, it remains sharply higher for the week, contributing to a rise in Treasury yields.Trade policy is also back in focus after the Trump administration announced new tariffs of 10% to 12.5% on imports from 60 countries, including China and several European nations. The measures have renewed concerns over global trade tensions and their potential impact on inflation, corporate margins and economic growth.In pre-market trading, S&P 500 futures rose 0.13%, Nasdaq futures rose 0.02% and Dow futures rose 0.33%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -Amkor Technologyup 12% after after disclosing a partnership with NvidiaOracleup 2% after being awarded a $3.31B Department of War Enterprise Software contractUP AFTER EARNINGS -Tenet Healthcareup 17%SLBup 4%Intelup 3%DOWN AFTER EARNINGS -MaxLineardown 7%Robert Halfdown 6%American Expressdown 4%Verizondown 1%HCA Healthcareup 1%Deckers Outdoordown 1%LOWER -Zevra Therapeuticsdown 25% after announcing that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a negative opinion regarding the marketing authorization application for arimoclomol for the treatment of Niemann-Pick disease type C
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.